Covid-19: Where are we on vaccines and variants?
Reads0
Chats0
TLDR
Mahase as mentioned in this paper reports on the latest developments in vaccines, variants, and diplomacy nearly a year after the WHO declared the covid-19 pandemic, and Elisabeth Mahase reports on vaccine variants, variants and diplomacy.Abstract:
Nearly a year after WHO declared the covid-19 pandemic, Elisabeth Mahase reports on the latest developments in vaccines, variants, and diplomacyread more
Citations
More filters
Journal ArticleDOI
SARS-CoV-2 variants, spike mutations and immune escape.
William T. Harvey,Alessandro M Carabelli,Ben Jackson,Ravindra K. Gupta,E. Thomson,E. Thomson,Ewan M. Harrison,Ewan M. Harrison,Catherine Ludden,Richard Reeve,Andrew Rambaut,Sharon J. Peacock,David Robertson +12 more
TL;DR: A review of the literature on mutations of the SARS-CoV-2 spike protein, the primary antigen, focusing on their impacts on antigenicity and contextualizing them in the protein structure is presented in this article.
Journal ArticleDOI
Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.
Michael I Barton,Stuart A. MacGowan,Mikhail A Kutuzov,Omer Dushek,Geoffrey J. Barton,P. Anton van der Merwe +5 more
TL;DR: Bart Barton et al. as discussed by the authors measured the effect of mutations in Spike and ACE2 on the strength of the interaction between the two proteins and found that three of the five common Spike mutations in the Alpha, Beta and Gamma SARS-CoV-2 variants strengthened binding to ACE2.
Posted ContentDOI
Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination.
Chris Davis,Nicola S Logan,Grace Tyson,Richard J. Orton,William T. Harvey,Jonathan S Perkins,Guy Mollett,Rachel M Blacow,Thomas P. Peacock,Wendy S. Barclay,Peter Cherepanov,Massimo Palmarini,Pablo R. Murcia,Arvind H. Patel,David Robertson,John Haughney,E. Thomson,E. Thomson,Brian J. Willett +18 more
TL;DR: In this paper, the authors examined the sensitivity of variants of concern (VOCs) representative of the B.617.1, B.1.2 and B.351 lineages of SARS-CoV-2 to neutralization by sera from individuals vaccinated with the BNT162b2 (Pfizer/BioNTech) and ChAdOx1 (Oxford/AstraZeneca) vaccines.
Journal ArticleDOI
SARS-CoV-2 new variants: Characteristic features and impact on the efficacy of different vaccines.
Abbas Khan,Taimoor Khan,Shughla Ali,Summiya Aftab,Yanjing Wang,Wang Qian-kun,Mazhar Khan,Muhammad Suleman,Shahid Ali,Wang Heng,Syed Shujait Ali,Dong-Qing Wei,Anwar Mohammad +12 more
TL;DR: In this paper, the emergence of new variants of SARS-CoV-2, their transmission risk, mortality rate, and the impact of each new variant on the efficacy of the developed vaccines reported in different literature and findings are explained.
Journal ArticleDOI
Relaxing restrictions at the pace of vaccination increases freedom and guards against further COVID-19 waves.
Simon Bauer,Sebastian Contreras,Sebastian Contreras,Jonas Dehning,Matthias Linden,Matthias Linden,Emil Iftekhar,Sebastian B. Mohr,Álvaro Olivera-Nappa,Viola Priesemann,Viola Priesemann +10 more
TL;DR: In this paper, an age-stratified SEIRD-ICU compartmental model and curated epidemiological and vaccination data were used to quantify the rate at which countries can lift non-pharmaceutical interventions without overwhelming their healthcare systems.
References
More filters
Journal ArticleDOI
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Denis Y. Logunov,Inna V. Dolzhikova,Dmitry V. Shcheblyakov,A. I. Tukhvatulin,Olga V. Zubkova,Alina S. Dzharullaeva,Anna V. Kovyrshina,Nadezhda L. Lubenets,Daria M. Grousova,Alina S. Erokhova,Andrei G. Botikov,Fatima M. Izhaeva,Olga Popova,Tatiana A Ozharovskaya,Ilias B Esmagambetov,Irina A Favorskaya,Denis I. Zrelkin,Daria V Voronina,Dmitry N. Shcherbinin,Alexander S. Semikhin,Yana V. Simakova,Elizaveta A. Tokarskaya,Daria A. Egorova,M M Shmarov,Natalia A. Nikitenko,Vladimir A. Gushchin,Elena A Smolyarchuk,Sergey Zyryanov,Sergei V. Borisevich,Boris S. Naroditsky,Alexander L. Gintsburg +30 more
TL;DR: Gam-COVID-Vac (Sputnik V) showed a good safety profile and induced strong humoral and cellular immune responses in participants in phase 1/2 clinical trials as discussed by the authors.
Journal ArticleDOI
Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant
TL;DR: The SARS-CoV-2 vaccine produced by the US biotechnology company Novavax is 956% effective against the original variant of SARS and also provides protection against the newer variants B117 (856%) and B1351 (60%) as mentioned in this paper.
Posted ContentDOI
A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New York
Medini K. Annavajhala,Hiroshi Mohri,Pengfei Wang,Manoj S. Nair,Jason Zucker,Zizhang Sheng,Angela Gomez-Simmonds,Anne L. Kelley,Maya Tagliavia,Yaoxing Huang,Trevor Bedford,David D. Ho,David D. Ho,Anne-Catrin Uhlemann +13 more
TL;DR: The emergence of a novel variant lineage B.1.526 that contains E484K and its alarming rise to dominance in New York City in recent months is reported in this article.
Journal ArticleDOI
Covid-19: Moderna vaccine is nearly 95% effective, trial involving high risk and elderly people shows
TL;DR: The UK government has secured five million doses of the covid-19 vaccine candidate mRNA-1273 from US biotech company Moderna after interim analysis of its phase III trial showed it was 94.5% effective.
Journal ArticleDOI
Covid-19: What have we learnt about the new variant in the UK?
TL;DR: The new SARS-CoV-2 variant has evoked scenes reminiscent of the early days of covid-19 when much of the world banned travel to and from Wuhan, China as mentioned in this paper.
Related Papers (5)
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Lindsey R. Baden,Hana M. El Sahly,Brandon Essink,Karen L. Kotloff,Sharon E. Frey,Rick Novak,David Diemert,Stephen A. Spector,Nadine Rouphael,C. Buddy Creech,John W McGettigan,Shishir Khetan,Nathan Segall,Joel Solis,Adam Brosz,Carlos Fierro,Howard J. Schwartz,Kathleen M. Neuzil,Lawrence Corey,Peter B. Gilbert,Holly Janes,Dean Follmann,Mary A. Marovich,John R. Mascola,Laura Polakowski,Julie E. Ledgerwood,Barney S. Graham,Hamilton Bennett,Rolando Pajon,Conor Knightly,Brett Leav,Weiping Deng,Honghong Zhou,Shu Liang Han,Melanie Ivarsson,Jacqueline Miller,Tal Z Zaks +36 more
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Merryn Voysey,Clemens Sac.,Shabir A. Madhi,Lily Yin Weckx,P M Folegatti,Parvinder K. Aley,Brian Angus,Vicky L. Baillie,Shaun Barnabas,Q E Bhorat,S Bibi,Carmen Briner,P Cicconi,Andrea M. Collins,R Colin-Jones,Clare L. Cutland,Thomas C. Darton,Keertan Dheda,Duncan Cja.,Emary Krw.,Katie J. Ewer,Lee Fairlie,Saul N. Faust,Shuo Feng,Daniela M. Ferreira,Adam Finn,Anna Goodman,Catherine M. Green,Christopher A Green,Paul T. Heath,Christopher Hill,Helen Hill,Ian Hirsch,Hodgson Shc.,Allen Izu,S Jackson,D Jenkin,Joe Ccd.,S Kerridge,Anthonet Koen,Gaurav Kwatra,Rajeka Lazarus,Alison M. Lawrie,A Lelliott,Vincenzo Libri,Patrick J. Lillie,R Mallory,Mendes Ava.,Eveline Pipolo Milan,Angela M. Minassian,Alastair McGregor,Hazel Morrison,Y Mujadidi,Amit J Nana,P J O’Reilly,S D Padayachee,A Pittella,E Plested,Katrina M Pollock,M N Ramasamy,S Rhead,Alexandre Vargas Schwarzbold,Nisha Singh,Andrew Smith,R Song,Matthew D. Snape,Eduardo Sprinz,Rebecca K. Sutherland,R Tarrant,E. Thomson,M E Török,Mark Toshner,Turner Dpj.,Johan Vekemans,Tonya Villafana,Watson Mee.,C J Williams,Alexander D. Douglas,Hill Avs.,Teresa Lambe,Sarah C. Gilbert,Andrew J. Pollard +81 more
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.
Nicholas G Davies,Sam Abbott,Rosanna C. Barnard,Christopher I Jarvis,Adam J. Kucharski,James D Munday,Carl A. B. Pearson,Timothy W Russell,Damien C. Tully,Alex D. Washburne,Tom Wenseleers,Amy Gimma,William Waites,Kerry L. M. Wong,Kevin van Zandvoort,Justin D. Silverman,Karla Diaz-Ordaz,Ruth H. Keogh,Rosalind M Eggo,Sebastian Funk,Mark Jit,Katherine E. Atkins,Katherine E. Atkins,W. John Edmunds +23 more